- Home
- KLAR vs LEGN Comparison
KLAR vs LEGN Comparison
Compare KLAR & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KLAR | LEGN |
|---|---|---|
| Founded | 2005 | 2014 |
| Country | United Kingdom | United States |
| Employees | 2831 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 5.9B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | KLAR | LEGN |
|---|---|---|
| Price | $16.48 | $29.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 12 |
| Target Price | $38.00 | ★ $61.33 |
| AVG Volume (30 Days) | ★ 5.7M | 2.3M |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $28.56 | $42.68 |
| Revenue Next Year | $19.93 | $30.52 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.06 | $16.24 |
| 52 Week High | $47.48 | $45.30 |
Technical Indicators
Market Signals| Indicator | KLAR | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 61.56 | 65.66 |
| Support Level | $12.77 | $25.01 |
| Resistance Level | $16.71 | $29.69 |
| Average True Range (ATR) | 0.93 | 2.17 |
| MACD | 0.19 | -0.12 |
| Stochastic Oscillator | 93.69 | 82.32 |
Price Performance
Historical ComparisonAbout KLAR Klarna Group plc Ordinary Shares
Klarna Group PLC is a technology-driven payments company, with operations spanning multiple countries. It connects consumers and merchants with comprehensive payment solutions and tailored advertising solutions, both online and offline. Its payment solutions provide consumers with more control and flexibility over their payments. It is a digital bank and flexible payments provider building the next-generation AI-powered commerce network.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.